EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting E3 ligases of the TRIM family for the development of next generation degraders

Rezart Zhubi iD, Stefan Knapp iD

Essays in Biochemistry · 06.11.2026

DOI: 10.1042/ebc20260004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Essays in Biochemistry, online erschienen am 06.11.2026. Verfasst von Rezart Zhubi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, 60438…. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targete protein degradation, driven by the clinical success of PROTACs (proteolysis targeting chimeras) and molecular glues, has significantlycontributed to the drug development pipeline. However, current degrader design predominantly relies on a limited set of E3 ubiquitin ligases, such as Cereblon and Von Hippel-Lindau. Exploring the chemical toolbox to include new, untargeted E3 ligases is important for developing degraders with new properties such as tissue-specific degradation. The present review highlights recent advancements in targeting the tripartite motif (TRIM) family of E3 ligases. Over the past 3 years, the discovery of TRIM ligands established the druggability of several members of this family, enabling the development of new degraders. However, so far reported ligands cover only two of the twelve known subclasses of this family. The present review focuses on ligands that target the substrate recruitment domain of TRIMs targeting the PRY-SPRY domains of TRIM7, TRIM21, TRIM25, and TRIM58, as well as the PHD-bromodomain of TRIM24 and TRIM33. Notably, some of these ligands have enabled the development of efficient PROTACs and molecular glues. For example, ligands for TRIM21 have been used for PROTAC development (TrimTACs) to degrade multimeric protein, and highly potent glues have been developed to degrade components of the nuclear pore complex. TRIM24 is not an active E3 ligase, but bromodomain ligands have been exploited for the development of TRIM24 degraders with potential applications in oncology. Thus, recent developments in TRIM-targeting ligands have significantly extended the toolbox for degrader development.

Schlagwörter

Stichwörter der Autor:innen

DegraderPROTACTRIM proteinubiquitin ligases

Autor:innen und Institutionen

  • Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, 60438 Frankfurt, Germany.
  • Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue-Straße 15, 60438 Frankfurt, Germany.
  • German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, 60438 Frankfurt, Germany.

ORCID-Profile: Rezart Zhubi, Stefan Knapp

Zitieren

APA

Zhubi, R., & Knapp, S. (2026). Targeting E3 ligases of the TRIM family for the development of next generation degraders. Essays in Biochemistry. https://doi.org/10.1042/ebc20260004

Vancouver

Zhubi R, Knapp S. Targeting E3 ligases of the TRIM family for the development of next generation degraders. Essays in Biochemistry. 2026. doi:10.1042/ebc20260004

BibTeX
@article{Zhubi2026,
  author = {Zhubi, Rezart and Knapp, Stefan},
  title = {Targeting E3 ligases of the TRIM family for the development of next generation degraders},
  journal = {Essays in Biochemistry},
  year = {2026},
  doi = {10.1042/ebc20260004}
}
Kostenlos starten →